Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00019435 · ClinicalTrials.gov registry record · Phase 1
LMB-9 Immunotoxin in Treating Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
NCT00019435: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00019435 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00019435, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: The LMB-9 immunotoxin may be able to locate tumor cells and kill them without harming normal cells. This may be an effective treatment for advanced solid tumors. PURPOSE: Phase I trial to study the effectiveness of LMB-9 immunotoxin in treating patients who have advanced solid tumors that have not responded to standard therapy.
Interventions
- BIOLOGICAL LMB-9 immunotoxin
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-05 |
| Phase | Phase 1 |
What the finished NCT00019435 record still lists
NCT00019435 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which LMB-9 immunotoxin is the first listed.
NCT00019435 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00019435 about?
NCT00019435 is a clinical study titled "LMB-9 Immunotoxin in Treating Patients With Advanced Solid Tumors". RATIONALE: The LMB-9 immunotoxin may be able to locate tumor cells and kill them without harming normal cells. This may be an effective treatment for advanced solid tumors. PURPOSE: Phase I trial to study the effectiveness of LMB-9 immunotoxin in treating patients who have advanced solid tumors tha...
What is the current status of trial NCT00019435?
This trial is currently completed. It is a Phase 1 study. The study started on 1998-05.
What interventions are being tested in trial NCT00019435?
The interventions under investigation include: LMB-9 immunotoxin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00019435?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia